Antibody: CD105, Clone: 2H6F11 , Isotype: IgG1, Conjugate: APC
- Known as:
- Antibody: CD105, Clone: 2H6F11 , Isotype: IgG1, Conjugate: Antigen presenting cellular
- Catalog number:
- 105A-100T
- Product Quantity:
- 100 test
- Category:
- -
- Supplier:
- Immunostep
- Gene target:
- Antibody: CD105 Clone: 2H6F11 Isotype: IgG1 Conjugate: APC
Related genes to: Antibody: CD105, Clone: 2H6F11 , Isotype: IgG1, Conjugate: APC
- Gene:
- ENG NIH gene
- Name:
- endoglin
- Previous symbol:
- ORW1, ORW
- Synonyms:
- END, HHT1, CD105
- Chromosome:
- 9q34.11
- Locus Type:
- gene with protein product
- Date approved:
- 1993-03-03
- Date modifiied:
- 2019-04-23
Related products to: Antibody: CD105, Clone: 2H6F11 , Isotype: IgG1, Conjugate: APC
Related articles to: Antibody: CD105, Clone: 2H6F11 , Isotype: IgG1, Conjugate: APC
- Achieving scalable and controlled production of nanovesicles remains a major bottleneck in translating nanocarrier systems to industry. Conventional batch methods, such as thin-film hydration and ethanol injection, often show low reproducibility, residual solvents, and multistep workflows that hinder scale-up. To address these challenges, we developed SuperSomes, a supercritical CO (SC-CO)-based process enabling continuous, solvent-free fabrication of nanovesicles. The method relies on atomization of an aqueous phase within a gas-expanded medium, promoting rapid self-assembly of surfactant or lipid molecules under mild conditions and allowing precise control over vesicle size and composition. As a proof of concept, we used SuperSomes to generate Span 80/Tween 80 or Span 80/Capric acid (C10) niosomes for oral drug delivery. By systematically tuning surfactant ratios, we identified how hydrophilic-lipophilic balance and packing parameters govern vesicle formation and stability. The resulting niosomes showed high resistance to pH and temperature variations. Caco-2 studies revealed enhanced intracellular uptake and paracellular transport, indicating a dual absorption mechanism. , orally administered fluorescent niosomes exhibited minimal gastric retention and improved intestinal permeation. Overall, SuperSomes offers a reproducible, scalable, and environmentally friendly platform for producing nanocarriers tailored for oral delivery, overcoming key limitations of conventional manufacturing approaches. - Source: PubMed
Tollemeto MatteoSarnelli Soniade Vittorio LauraRubio-Huertas MartaBaldino LuciaBoisen Anja - This eight-year study characterized trace compounds in grid-injected biomethane from methanization using a multi-analytical strategy combining broad thermal desorption gas chromatography-mass spectrometry (TD-GC/MS) screening with targeted quantitative methods. Between 2016 and 2023, 75 sampling campaigns were conducted at 40 French biomethane injection plants, covering diverse feedstocks and upgrading technologies. 530 organic compounds across nine chemical families were identified by TD-GC/MS. Of these, 65 calibrated compounds were quantified and 465 non-target compounds were semi-quantitatively estimated as order-of-magnitude concentrations. Most compounds occurred sporadically and at low levels: only 100 were detected in more than ten samples, whereas 207 appeared only once, with an average of 48 trace compounds per sample. Average concentrations were generally low, with only 13 % exceeding 100 µg/Nm. Hydrocarbons were dominant, followed by oxygenated compounds, while terpenes, organic sulfur compounds, siloxanes, halocarbons and amines occurred less frequently. Chemometric analysis of 45 selected TD-GC/MS compounds showed broadly similar biomethane trace profiles, with no robust clustering by feedstock or upgrading technology. Targeted analyses quantified compounds of regulatory or operational relevance, including monoaromatic hydrocarbons, terpenes, sulfur species, ammonia, mercury and trace elements. Regulated sulfur species, ammonia, mercury and siloxanes remained below current injection requirements, and compounds shared with conventional natural gas were generally comparable to or lower than natural-gas reference levels. This information-rich dataset demonstrates the complementarity of analytical strategies and shows that grid-injected biomethane contains a chemically diverse but low-abundance trace-compound fraction, supporting secure grid integration and future monitoring, standardization and specification evolution. - Source: PubMed
Publication date: 2026/09/05
Sanz BéatriceLouvat AmélieVorin DjimmyDupré LucieLegendre AgatheCuccia LorenaDisdier ZoéPale-Guerquin MaïlysTena EmmanuelJosi LéaCaumette GuilhemVial JérômeCastro Dairo Ballestas - CD38 is a highly conserved multifunctional enzyme that regulates intracellular calcium signaling and NAD⁺ metabolism. Although extensively studied in cancer and autoimmune diseases, growing evidence points to a critical role for CD38 in both normal and diseased liver physiology. In hepatic tissue, CD38 is expressed on multiple cell types. Aberrant CD38 activity contributes to increased oxidative stress, inflammation, and diminished tissue repair. Recent studies suggest that CD38 may also promote cellular senescence partly through its regulation of intracellular NAD⁺ and calcium. This review examines the role of CD38 in maintaining hepatic homeostasis and explores its involvement in liver injury, chronic liver diseases, and carcinogenesis. We also highlight the contribution of CD38-mediated signaling to hepatic fibrogenesis and end-stage liver failure as well as its potential role in liver transplantation, particularly post-transplant related conditions including ischemic injury and acute cellular rejection. Given its impact on multiple intracellular processes, CD38 has emerged as a promising therapeutic target. New findings describe how CD38 inhibition preserves NAD⁺ levels, supports tissue recovery, and mitigates disease progression in the liver. Finally, we outline new frontiers for CD38 in liver biology and the advancement of CD38-targeted therapeutic strategies. - Source: PubMed
Publication date: 2026/09/05
Eng Jason WPeterson Blake RBlack Sylvester - Bone formation is tightly regulated by osteoblasts, which secrete extracellular matrix (ECM) components and heterogeneous populations of extracellular vesicles (EVs). Among EVs, matrix vesicles (MVs) are uniquely associated with mineralization and act as bioactive extracellular nanostructures that initiate and spatially direct mineral growth within the ECM. However, how MVs interact with the ECM and how their functions differ from the functions of medium-derived EVs (mEVs) remain unclear. To address this question, we developed a bioinspired collagen-based scaffold designed to mimic the bone ECM organic phase and to recreate MV-mediated mineralization in vitro. Type I collagen scaffolds were slowly concentrated and exposed to NH3(g) to induce fibrillogenesis and stabilize supramolecular organization, while 5 wt % κ-carrageenan, a sulfated polysaccharide that functionally emulates glycosaminoglycans, was incorporated to support mineral nucleation. MC3T3-E1 pre-osteoblasts were cultured under osteogenic conditions to induce differentiation and vesicle secretion. Biochemical, microscopic, and spectroscopic analyses revealed that MVs and mEVs exhibit distinct nano-biointerface behaviors, particularly regarding ECM anchoring and the ability to initiate mineral deposition. Furthermore, Raman chemical imaging and X-ray nanotomography demonstrated that MVs not only trigger mineral formation but also direct the spatial organization of phosphate deposition within the ECM at the micro/nanoscale. By distinguishing MV- from mEV-mediated mineralization in a biomimetic ECM system, this study provides new insights into vesicle-guided biomineralization and spatial matrix organization, with implications for skeletal development, pathological calcification, and vesicle-based regenerative strategies. - Source: PubMed
Publication date: 2026/09/05
Nogueira Lucas Fabricio BahiaSilva Yuri Ferreira dade Melo Maryanne TrafaniCominal Juçara Gastaldida Silva Keteryne RodriguesFukada Sandra YasuyoAlmeida FaustoPerré PatrickAugusto Pedro E DCiancaglini PietroRamos Ana Paula - Ultrasound-activated perfluorocarbon nanodroplets (NDs) have potential as circulating agents for non-invasive, targeted drug delivery. NDs can be induced to cavitate under focussed ultrasound stimulation, releasing a therapeutic payload. They have been explored widely as a means of drug delivery in oncology but there is less information available on their use in regenerative medicine. Here, we tested the hypothesis that NDs could be fabricated to incorporate an agonist of Wnt signalling, a pathway common to many regenerative tissue-specific processes, and to release it in active form upon ultrasound stimulation. NDs were formed by ultrasonic emulsification of perfluorobutane in the presence of 6-bromoindirubin-3-oxime (BIO) and phospholipids: DSPC and DSPE-PEG2000. The nanodroplet formulation (∼200 nm diameter and 5 × 10 mL) was stable in aqueous suspension for up to 10 days at 4 °C, but gradual passive release of BIO was observed over a period of hours (15-30% release in 24 hours) in serum-containing growth medium at 37 °C, as measured by high pressure liquid chromatography. NDs were not toxic to either primary or continuous bone-derived cells and induced signalling in a 3T3 Wnt reporter cell line, indicating that the released BIO was active. Rapid release of BIO was achieved by exposing NDs to ultrasound. 25% BIO release was observed after 30 s of exposure to ultrasound (0.9 MHz centre frequency, 0.75 MPa peak negative pressure, 1 kHz pulse repetition frequency, 10% duty cycle) and activated Wnt signalling in cells. Our data indicate that NDs may be used to incorporate and deliver a Wnt pathway activator in response to ultrasound stimulation and that they have potential as drug delivery agents for regenerative medicine applications. - Source: PubMed
Publication date: 2026/07/13
Polydorou AnastasiaWu QiangBen Issa AyaMay Jonathan PFerri SaraCarugo DarioStride EleanorEvans Nicholas D